Document is current
Any future updates will be listed below
-
Authors
Cosgun, Kadriye Nehir
Jumaa, Huda
Robinson, Mark E.
Cheng, Zhangliang
Oulghazi, Salim
Kume, Kohei https://orcid.org/0000-0003-2856-5970
Fonseca Arce, David
Agadzhanian, Nikol
Kistner, Klaus M.
Leveille, Etienne
Drivet, Elsa https://orcid.org/0009-0006-3481-4071
Yu, Fang
Qian, Zhijian
Song, Joo Y.
Chan, Wing-Chung https://orcid.org/0000-0002-6243-6008
Xu, Liang
Xiao, Gang https://orcid.org/0000-0002-9476-3847
Taketo, M. Mark https://orcid.org/0000-0002-9032-4505
Kothari, Shalin
Davids, Matthew S. https://orcid.org/0000-0003-4529-2003
Schjerven, Hilde https://orcid.org/0000-0001-9287-3375
Jellusova, Julia https://orcid.org/0000-0002-5234-2104
Müschen, Markus https://orcid.org/0000-0002-6064-8613
-
Funding
Funding for this research was provided by:
Howard Hughes Medical Institute (HHMI-55108547)
- License Information
-
More Information
Article History
Received: 22 February 2025
Accepted: 10 November 2025
First Online: 8 January 2026
Competing interests
: M.M. discloses filing of Yale University patent application PCT/US2023/067398. S.K. reports consulting or advisory roles for Eli Lilly, ADC Therapeutics, AbbVie, Genentech and Incyte, and research funding from Bristol Myers Squibb. M.S.D. reports consulting or advisory roles for AbbVie, Ascentage Pharma, AstraZeneca, BeOne Medicines, Bristol Myers Squibb, Eli Lilly, Genentech, Genmab, Janssen, MEI Pharma, Merck, Nuvalent and Schrӧdinger, and research funding from Ascentage, AstraZeneca, MEI Pharma and Novartis.
